Welcome
Pharmaceutical & Life Sciences News

Shire, Fresenius Drop Firazyr Patent Dispute on Eve of Appeal

Nov. 16, 2018, 5:38 PM

Shire Plc subsidiary Shire Orphan Therapies LLC and Fresenius Kabi USA LLC ended their dispute over a drug patent covering the hereditary angioedema (HAE) treatment Firazyr.

The companies agreed to drop the litigation over Fresenius’s proposed generic version of the $1.2 billion drug just before the U.S. Court of Appeals for the Federal Circuit was scheduled to hear Fresenius’s appeal. The appeals court was set to hear argument Dec. 3 but instead dismissed the case Nov. 16.

The case involved a patent for Firazyr expiring in July 2019. This June, Judge Gregory M. Sleet of the U.S. District Court for...

To read the full article log in. To learn more about a subscription click here.